A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00623116 |
Recruitment Status :
Enrolling by invitation
First Posted : February 25, 2008
Last Update Posted : February 25, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Kallmann Syndrome | Drug: Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Kallmann Syndrome in Finland |
Study Start Date : | December 2007 |
Estimated Primary Completion Date : | December 2012 |
Estimated Study Completion Date : | December 2025 |

- Drug: Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)
clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
- Clinical features including quality of life, reversibility and genetic features of Kallmann syndrome in Finland [ Time Frame: 0, 3 mo and during subsequent F/U ]
- epidemiology [ Time Frame: by 2012 (anticipated) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Kallmann syndrome
- Age 15 yrs or more
Exclusion Criteria:
- Severe mental retardation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00623116
Finland | |
Hospital for Children and Adolescents, Helsinki University Central Hospital | |
Helsinki, Finland, 00029 HUCH |
Study Director: | Taneli J Raivio, MD PhD | Hospital for Children and Adolescents, Helsinki University Central Hospital |
Responsible Party: | Taneli Raivio, MD, Ph D, Hospital for Children and Adolescents, Helsinki University Hospital |
ClinicalTrials.gov Identifier: | NCT00623116 |
Other Study ID Numbers: |
231408 286/E7/2007 |
First Posted: | February 25, 2008 Key Record Dates |
Last Update Posted: | February 25, 2008 |
Last Verified: | January 2008 |
Kallmann Syndrome hypogonadotropic hypogonadism |
Kallmann Syndrome Syndrome Disease Pathologic Processes Disorder of Sex Development, 46,XY Disorders of Sex Development Urogenital Abnormalities Congenital Abnormalities Genetic Diseases, Inborn |
Gonadal Disorders Endocrine System Diseases Hypogonadism Testosterone Estrogens Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs |